long intergenic non-protein coding RNA 1890Genealiases: []
Q-omics provides the consensus-scored LINC01890 profile across patient tissues and cancer cell-line models. LINC01890 expression is associated with patient survival in 13 of 34 cancer types, with the highest sampling consensus in HNSC. Among the 18 cancer types available for tumor–normal comparison, LINC01890 is differentially expressed in 5, with the highest sampling consensus in BRCA. Additionally, LINC01890 RNA expression shows 8,347 significant protein co-abundance associations, with the highest sampling consensus in LSCC. Together, these results highlight HNSC, BRCA, and LSCC as cancer lineages where LINC01890 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01890 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01890 survival associations across molecular data types. LINC01890 RNA expression shows survival associations in the most cancer types (13). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01890 RNA expression–survival associations across cancer types. High LINC01890 expression shows unfavorable associations in READ, KICH, COAD and LUSC, but favorable associations in HNSC and SKCM. The HNSC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p = .005). Together, the overview and detailed table identify HNSC as the clearest survival context for LINC01890 RNA expression.
This table summarizes LINC01890 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 5. The strongest signals are observed in BRCA for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01890. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01890 shows lower tumor expression in BRCA, LUAD, PAAD and LUSC and higher tumor expression in KIRC. The BRCA box plot shows higher LINC01890 RNA expression in normal versus tumor tissue (log2 FC = −0.024, t-test p = .001).
This table shows molecular features associated with LINC01890 in patient tissues and cancer cell lines. In patient samples, LINC01890 shows the broadest associations at the RNA and protein expression levels, with LSCC recurring as the lineage with the largest associated feature set.
